GLAUKOS Corp.
- GKOS ยท NYSE
- Surgical & Medical Instruments & Apparatus
- Aliso Viejo, CA
- 1,094 employees
- CIK 0001192448
Updated from SEC filings through
Top things to know
Executives
- Thomas Burns Glaukos chairman and chief executive officer 8-K, 2026-10-28
-
Thomas William Burns CHAIRMAN & CEO 4, 2026-06-29 - Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER 4, 2026-08-11
- Alex Thurman Senior Vice President and Chief Financial Officer 10-K, 2026-02-23
-
Tomas Navratil CHIEF DEVELOPMENT OFFICER 4, 2026-09-28 -
Joseph E. Gilliam PRESIDENT & COO 4, 2026-08-13
What leadership is saying
“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa”
Earnings press release (8-K Ex. 99.1), filed October 28, 2026
GLAUKOS Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Aliso Viejo, CA. It trades as GKOS on NYSE. Revenue was $507M in the fiscal year ending December 31, 2025, +32.3% from the year before. It reported about 1,094 employees. Thomas Burns is Glaukos chairman and chief executive officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $507M 10-K, 2026-02-23 | $383M 10-K, 2026-02-23 | $315M 10-K, 2026-02-23 | $283M 10-K, 2025-02-25 | $294M 10-K, 2024-02-23 |
| Operating income | -$200M 10-K, 2026-02-23 | -$122M 10-K, 2026-02-23 | -$129M 10-K, 2026-02-23 | -$82.3M 10-K, 2025-02-25 | -$32.9M 10-K, 2024-02-23 |
| SG&A | $332M 10-K, 2026-02-23 | $261M 10-K, 2026-02-23 | $224M 10-K, 2026-02-23 | $193M 10-K, 2025-02-25 | $179M 10-K, 2024-02-23 |
| Net income | -$188M 10-K, 2026-02-23 | -$146M 10-K, 2026-02-23 | -$135M 10-K, 2026-02-23 | -$99.2M 10-K, 2025-02-25 | -$49.6M 10-K, 2024-02-23 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Thomas Burns | Glaukos chairman and chief executive officer | 8-K, 2026-10-28 |
| Thomas William Burns | CHAIRMAN & CEO | 4, 2026-06-29 |
| Thomas W. Burns | Named in proxy bio: Chairman and Chief Executive Officer | DEF 14A, 2026-04-16 |
| Denice M. Torres | Board member (per proxy) bio: Chief Executive Officer | DEF 14A, 2026-04-16 |
| Marc A. Stapley | Board member (per proxy) bio: Chief Executive Officer | DEF 14A, 2026-04-16 |
| Alex R. Thurman Senior Vice President and Chief Financial Officer at Glaukos Corporation | SVP & CHIEF FINANCIAL OFFICER | 4, 2026-08-11 |
| David F. Hoffmeister | Board member (per proxy) bio: Former Senior Vice President and Chief Financial Officer | DEF 14A, 2026-04-16 |
| Alex Thurman | Senior Vice President and Chief Financial Officer | 10-K, 2026-02-23 |
| Tomas Navratil Chief Development Officer at Glaukos (R&D, Engineering, Clinical Development, Regulatory Affairs) | CHIEF DEVELOPMENT OFFICER | 4, 2026-09-28 |
| Joseph E. Gilliam President & Chief Operating Officer at Glaukos | PRESIDENT & COO | 4, 2026-08-13 |
| Aimee S. Weisner | Board member (per proxy) bio: Former Corporate Vice President and General Counsel | DEF 14A, 2026-04-16 |
| Gilbert H. Kliman, MD | Board member (per proxy) bio: Managing Partner | DEF 14A, 2026-04-16 |
| Leana S. Wen, MD | Board member (per proxy) bio: Emergency Physician and Adjunct Associate Professor, George | DEF 14A, 2026-04-16 |
| Mark J. Foley | Board member (per proxy) bio: Lead Independent Director | DEF 14A, 2026-04-16 |
What GLAUKOS Corp does
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 59.2 million (as of October 26, 2026) | 10-Q, October 28, 2026 |
|---|---|---|
| Public float | $5.9B (as of June 30, 2025) | 10-K, February 23, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 28, 2026 |
| Latest proxy statement | Meeting May 28, 2026 (filed April 16, 2026) | DEF 14A, April 16, 2026 |
| Auditor | Ernst & Young LLP (Irvine, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 4, 2026 | Gilbert H. Kliman Director | Sale | 2,500 | $633K | Form 4, November 5, 2026 |
| October 30, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sale | 44,436 | $10.6M | Form 4, November 3, 2026 |
| October 5, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sale | 1,527 | $251K | Form 4, October 7, 2026 |
| September 25, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sale | 1,615 | $249K | Form 4, September 28, 2026 |
| September 16, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sale | 1,457 | $243K | Form 4, September 18, 2026 |
| August 28, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sale | 13,744 | $2.5M | Form 4, September 1, 2026 |
| August 19, 2026 | Gilbert H. Kliman Director | Sale | 2,500 | $475K | Form 4, August 20, 2026 |
| August 11, 2026 | Joseph E. Gilliam PRESIDENT & COO | Sale | 60,000 | $10.8M | Form 4, August 13, 2026 |
Recent 8-K events
- 8-K filed 2026-11-06
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-28
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-03
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-03
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-04
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-02
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-17
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-01-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about GLAUKOS Corp
- What does GLAUKOS Corp do?
- In its own words, from Item 1 of its 10-K: "Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012."
- What is GLAUKOS Corp's revenue?
- $507M for the fiscal year ending December 31, 2025, from its 10-K filed February 23, 2026.
- Is GLAUKOS Corp profitable?
- GLAUKOS Corp reported net income of -$188M for the fiscal year ending December 31, 2025.
- How many employees does GLAUKOS Corp have?
- About 1,094 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of GLAUKOS Corp?
- Thomas Burns, Glaukos chairman and chief executive officer, as named in a 8-K filed October 28, 2026.
- Who is the CFO of GLAUKOS Corp?
- Alex R. Thurman, SVP & CHIEF FINANCIAL OFFICER, as named in a 4 filed August 11, 2026.
- Where is GLAUKOS Corp headquartered?
- Aliso Viejo, CA.
- What is GLAUKOS Corp's stock ticker?
- GKOS on NYSE.
- What industry is GLAUKOS Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is GLAUKOS Corp's website?
- glaukos.com.
- When does GLAUKOS Corp report earnings next?
- December 28, 2026. Source: estimate_8k_pattern.
- Is GLAUKOS Corp a public company?
- Yes. GLAUKOS Corp files with the SEC under CIK 0001192448 and trades as GKOS.
- Who audits GLAUKOS Corp?
- Ernst & Young LLP, Irvine, California, as named in its latest annual report (10-K).
- How many shares of GLAUKOS Corp are outstanding?
- 59.2 million shares as of October 26, 2026, from its 10-Q filed October 28, 2026.
- What is GLAUKOS Corp's public float?
- $5.9B as of June 30, 2025, as reported on the cover of its 10-K filed February 23, 2026.
- How many business segments does GLAUKOS Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 28, 2026.
- When is GLAUKOS Corp's annual shareholder meeting?
- May 28, 2026, per its proxy statement (DEF 14A) filed April 16, 2026.
- Have GLAUKOS Corp insiders traded stock recently?
- Since September 11, 2025, officers and directors reported 35 open-market sales worth about $81.1M and 0 purchases on Forms 4 and 5. The most recent: Gilbert H. Kliman (Director) sold 2,500 shares on November 4, 2026.